Gyre Therapeutics Files 8-K on Director/Officer Changes
Ticker: GYRE · Form: 8-K · Filed: Aug 22, 2025 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
TL;DR
Gyre Therapeutics is shuffling its board and execs, filing an 8-K with leadership changes.
AI Summary
Gyre Therapeutics, Inc. (formerly Catalyst Biosciences, Inc.) filed an 8-K on August 22, 2025, reporting events as of August 18, 2025. The filing covers the departure of directors, election of directors, appointment of officers, and compensatory arrangements. It also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This filing indicates significant changes in the company's leadership and governance structure, which could impact its strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers can signal underlying issues or strategic shifts that may affect the company's future performance.
Key Players & Entities
- GYRE THERAPEUTICS, INC. (company) — Registrant
- CATALYST BIOSCIENCES, INC. (company) — Former Company Name
- TARGACEPT INC (company) — Former Company Name
- August 18, 2025 (date) — Date of earliest event reported
- August 22, 2025 (date) — Filing Date
FAQ
What specific changes were made to Gyre Therapeutics' board of directors?
The filing indicates the departure of directors and the election of new directors, though specific names are not detailed in the provided text.
Were there any changes in the company's executive officer positions?
Yes, the filing mentions the appointment of certain officers, suggesting changes in executive roles.
What is the significance of the 'Regulation FD Disclosure' item?
This indicates that the company is making public disclosures to prevent selective disclosure of material non-public information.
When was Gyre Therapeutics, Inc. previously known as Catalyst Biosciences, Inc.?
The date of the name change from Catalyst Biosciences, Inc. to Gyre Therapeutics, Inc. was August 20, 2015.
What is the primary business of Gyre Therapeutics, Inc. according to its SIC code?
Gyre Therapeutics, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Stats: 898 words · 4 min read · ~3 pages · Grade level 10.5 · Accepted 2025-08-22 07:05:42
Filing Documents
- ef20054243_8k.htm (8-K) — 33KB
- ef20054243_ex99-1.htm (EX-99.1) — 7KB
- image001.jpg (GRAPHIC) — 7KB
- 0001140361-25-032295.txt ( ) — 181KB
- gyre-20250818.xsd (EX-101.SCH) — 4KB
- gyre-20250818_lab.xml (EX-101.LAB) — 21KB
- gyre-20250818_pre.xml (EX-101.PRE) — 16KB
- ef20054243_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated August 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: August 22, 2025 By: /s/ Ping Zhang Name: Ping Zhang Title: Executive Chairman and Interim Chief Executive Officer